Alterity Therapeutics Enrolls First Patient in Italy in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
Posted: 8 March 2023 Alterity Therapeutics, a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the first participant in Italy has been dosed in the Company’s Phase 2 clinical trial of ATH434 in…
Revolutionary new cholesterol drug to save lives
Posted: 7 March 2023 Hundreds of thousands of Australians with life-threatening high cholesterol are set to benefit from a revolutionary new pill following the successful research and trial by Professor Stephen Nicholls, Director of the Victorian Heart Institute and Victorian Heart…
Better detection of hepatitis B and hepatitis C will reduce the risk of cancer
Posted: 7 March 2023 Over 200,000 people in Australia live with hepatitis B and over 100,000 people with hepatitis C, and have a greater risk of liver cancer – one of the leading causes of cancer death in…
Doherty researchers develop world-first AMR detection tool
Posted: 7 March 2023 A new tool that could soon revolutionise the way we identify antimicrobial resistance (AMR) has been developed by researchers at the University of Melbourne’s Microbiological Diagnostic Unit Public Health Laboratory (MDU PHL), located at…
Optiscan Imaging Featured in Australian Financial Review
Posted: 6 March 2023 Real-time pathology for surgeons When it comes to medical diagnostic procedures such as age-old X-rays, time seems to have stood still despite the astounding technological advancements over the last two decades. In the case…
New hydrogel stem cell treatment repairs injured brain tissue in mice
A new ‘hybrid’ hydrogel, which allows clinicians to safely deliver stem cells to the site of a brain injury in mice, has been developed by researchers from the University of Melbourne and the Australian National University. A hydrogel…
Imagion receives 2nd CSIRO Federal Government grant for prostate cancer project
Posted: 2 March 2023 Imagion Biosystems Limited, a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to announce that it has qualified for a second grant of $50,000 under the Entrepreneurs’ Programme of…
Peter MacCallum Cancer Centre and Cartherics Announce Collaboration to Develop Autologous CAR-T Cell Therapy for Ovarian Cancer
Posted: 1 March 2023 Peter MacCallum Cancer Centre (“Peter Mac”) and Cartherics Pty Ltd (“Cartherics”) announced they have entered into a Collaborative Development Program Agreement (CDPA) to develop Cartherics’ proprietary autologous CAR-T cell therapy (CTH-004) for the treatment…
Investing in a stronger, healthy region
Posted: 24 February 2023 Australia will invest in high-quality health programs across the Pacific and Southeast Asia as part of the Partnerships for a Healthy Region initiative, a new five-year program to improve health outcomes and promote regional…
Burnet welcomes announcement of regional health investment package
Posted: 24 February 2023 Burnet Institute has welcomed the Australian government’s announcement of an investment package that aims to help build a stronger and more resilient Asia-Pacific. Foreign Minister Penny Wong and Minister for International Development and the…
First Gene Therapy for Hemophilia B, CSL’s HEMGENIX®, Approved by the European Commission
Posted: 24 February 2023 Global biotechnology leader CSL (ASX: CSL) today announced that the European Commission has granted conditional marketing authorization (CMA) for HEMGENIX® (etranacogene dezaparvovec), the first and only one-time gene therapy for the treatment of severe and moderately severe…
Firebrick Pursues Development of Nasodine for Use in Children
Posted: 23 February 2023 Firebrick Pharma announced plans to develop Nasadine Nasal Spray for use in children as well as adults. The plans were outlined in a Paediatric Investigation Plan (PIP) that was filed with the European Medicines…
